Pregabalin

CLINICAL USE

Anti-epileptic agent Neuropathic pain Generalised anxiety disorder

DOSE IN NORMAL RENAL FUNCTION

150–600 mg daily in 2 or 3 divided doses

PHARMACOKINETICS

Molecular weight :159.2

%Protein binding :0

%Excreted unchanged in urine : 92–99

Volume of distribution (L/kg) :0.56

half-life – normal/ESRD (hrs) :5–6.5/ Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–60 Initial dose 75 mg daily and titrate according to tolerability and response15–30 Initial dose 25–50 mg daily and titrate according to tolerability and response<15 Initial dose 25 mg daily and titrate according to tolerability and response

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Dialysed. Dose as in GFR<15 mL/min

HD :Dialysed. Dose as in GFR<15 mL/min

HDF/high flux :Dialysed. Dose as in GFR<15 mL/min

CAV/VVHD :Dialysed. Dose as in GFR=15–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Oral bioavailability >90% 50% of dose is removed after a 4 hour haemodialysis sessionUse with caution in people with severe congestive heart failure. May cause reversible deterioration in renal function.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home